NCT02903160 - Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2017

Primary Completion Date

November 15, 2021

Study Completion Date

November 15, 2021

Conditions

Prostate Cancer

Interventions

DRUG

Abiraterone acetate

Abiraterone acetate 1000 mg PO daily

DRUG

Prednisone

5 mg PO twice a day

DRUG

Radium-223 dichloride

50 kBq/kg IV monthly

DRUG

cabazitaxel

25 mg/m2 IV every 3 weeks

DRUG

Carboplatin

Carboplatin AUC 4 IV every 3 weeks

DRUG

Enzalutamide

160 mg PO daily

Trial Locations (2)

Mount Sinai Beth Israel, New York

Icahn School of Medicine at Mount Sinai, New York